Sanofi and Mass General Brigham contributed to a round that pushed the immunotherapy developer's total funding to nearly $60m.

Cambrian Biopharma returned to back the immunotherapy developer's series B round, following its series A three months ago.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

GV and Nextech contributed to a series B round that boosted the affordable pharmaceutical developer's overall funding to $750m.

Hepalink will exit the immune and inflammatory disease drug developer in an acquisition that could reach $1.45bn in size.

The brain disease treatment developer was founded in 2019 on the back of more than a decade’s collaborative research from MIT and Harvard.

Lilly Asia Ventures, a regional corporate venturing subsidiary of pharmaceutical firm Eli Lilly, reinvested in a round set to accelerate development of Abbisko's cancer-focused drug candidates.

GV, MRL Ventures Fund and WuXi Healthcare Ventures participated in a series B round that lifted the small molecule therapy developer's overall funding to $120m.

Takeda Digital Ventures, Humana, McKesson Ventures and dRx Capital backed the online pharmacy platform developer's series B round.

Fidelity provided a $4.8m second tranche after a first close featuring KNC, Ohar Pharmaceutical, Spera Pharma, Kisco and SRD Holdings.